Asiri Abdullah M, Rafie Mohamed A, Alalawi Mohamed M, Farouqi Umar S, Alguthayr Khalid M, Aboud Atheer, Khan Adeel, Khan Shahista R, Aljuffairi Eman, AlHashimi Fatima
Training, King Hamad University Hospital, Busaiteen, BHR.
Urology, King Hamad University Hospital, Busaiteen, BHR.
Cureus. 2025 Apr 10;17(4):e82023. doi: 10.7759/cureus.82023. eCollection 2025 Apr.
Renal cell carcinoma (RCC) metastasis to the urinary bladder has been a rarely reported clinical entity, and its potential metachronous pathobiological process poses significant challenges in RCC therapy-transforming scenarios. In this case, we share the experience of a female patient who underwent radical nephrectomy in September 2020 and was on regular follow-up. In March 2022, she was found to have right pulmonary metastasis on PET-CT imaging and accordingly underwent right-sided wide local excision of the lung lesion by thoracoscopy in June 2022, which revealed metastatic clear cell RCC. She was kept on immunotherapy as discussed in the tumor board meeting and was followed up. Uncommonly, in November 2022, a bladder growth was found involving the left vesicoureteric junction on follow-up CT scan, due to hematuria occurring two years after nephrectomy. Histopathologic examination revealed this mass to be an RCC metastasis. The subsequent imaging diagnosis led to an aggressive treatment approach, resulting in cystectomy with anterior exenteration and ileal conduit. This case is unique in Bahraini literature, as it highlights the unpredictable patterns of RCC metastasis and the infrequent occurrence of the bladder as the site of such metastasis. This report attempts to dissect the intricacies of RCC metastases to the bladder by providing an accurate perspective on diagnosing and managing such atypical sites through a literature review and in-depth discussion of histopathological characteristics. It highlights the importance of an aggressive follow-up regimen for RCC patients, potentially irrespective of their primary site appearing well contained. It would add to our understanding of a broader spectrum of RCC metastatic disease.
肾细胞癌(RCC)转移至膀胱是一种临床报道较少见的情况,其潜在的异时性病理生物学过程在RCC治疗转变的场景中带来了重大挑战。在此病例中,我们分享一位女性患者的经历,她于2020年9月接受了根治性肾切除术并进行定期随访。2022年3月,她在PET-CT成像中被发现有右肺转移,因此于2022年6月通过胸腔镜对肺部病变进行了右侧广泛局部切除,结果显示为转移性透明细胞RCC。按照肿瘤委员会会议讨论的方案,她继续接受免疫治疗并进行随访。不同寻常的是,2022年11月,在随访CT扫描中发现膀胱肿物累及左输尿管膀胱连接部,这是在肾切除术后两年出现血尿后发现的。组织病理学检查显示该肿物为RCC转移灶。随后的影像学诊断导致采取积极的治疗方法,即膀胱切除加前盆腔脏器清除术及回肠代膀胱术。该病例在巴林文献中是独特的,因为它突出了RCC转移的不可预测模式以及膀胱作为此类转移部位的罕见情况。本报告试图通过文献综述以及对组织病理学特征的深入讨论,对诊断和管理此类非典型部位提供准确观点,从而剖析RCC转移至膀胱的复杂性。它强调了对RCC患者采取积极随访方案的重要性,可能无论其原发部位看起来是否得到良好控制。这将增进我们对更广泛的RCC转移性疾病的理解。